111In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 7, 2010, Pages 1441-1448

  Bombardieri, Emilio ^a   Ambrosini, Valentina ^b   Aktolun, Cumali ^c   Baum, Richard P ^d   Bishof Delaloye, Angelica ^e   Del Vecchio, Silvana ^f   Maffioli, Lorenzo ^g   Mortelmans, Luc ^h   Oyen, Wim ⁱ   Pepe, Giovanna ^j   Chiti, Arturo ^j  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c KOCAELI UNIVERSITY   (Turkey)

^d PET Center   (Germany)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g Ospedale di Legnano   (Italy)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^j HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

more..

Author keywords

111In pentetreotide scintigraphy; Indications; Neuroendocrine tumours; Procedure guidelines; Tumour imaging

Indexed keywords

DOTA NOC GA 68; DOTA TATE GA 68; DOTA TOC GA 68; GASTRIN; GLUCAGON; GLUCOSE; INSULIN; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

AGE DISTRIBUTION; ASTROCYTOMA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BREAST; BREAST CANCER; BREAST CARCINOMA; BREAST FEEDING; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOID; CECUM; COLON; DIABETES MELLITUS; DIABETIC PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MEGADOSE; DRUG QUALITY; DRUG RECEPTOR BINDING; DRUG UPTAKE; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; GALLBLADDER; GANGLIONEUROMA; GASTRIN BLOOD LEVEL; GASTRINOMA; GLUCAGON BLOOD LEVEL; GLUCAGONOMA; GLUCOSE METABOLISM; GRANULOMA; HUMAN; HYPOGLYCEMIA; HYPOPHYSIS ADENOMA; IMAGE ANALYSIS; IMAGE PROCESSING; INFLAMMATORY DISEASE; INSULINOMA; INTESTINE INJURY; KIDNEY; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LIVER; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTE; LYMPHOMA; MEDICAL EXAMINATION; MELANOMA; MENINGIOMA; MERKEL CELL TUMOR; MOLECULAR IMAGING; NEOPLASM; NEUROBLASTOMA; NUCLEAR MEDICINE; PARAGANGLIOMA; PARENTERAL NUTRITION; PATIENT MONITORING; PATIENT SELECTION; PHEOCHROMOCYTOMA; PHYSICIAN; PLEURA; PRACTICE GUIDELINE; PREGNANCY; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; QUALITY CONTROL; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOISOTOPE THERAPY; REVIEW; SARCOMA; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; THERAPEUTIC ERROR; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUMOR DIFFERENTIATION; TUMOR SCINTISCANNING; UNDIFFERENTIATED CARCINOMA; URINARY EXCRETION; VIPOMA; ARTICLE; COMPUTER ASSISTED DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INSTRUMENTATION; METABOLISM; METHODOLOGY; SCINTISCANNING;

FEMALE; GAMMA CAMERAS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NEOPLASMS; PREGNANCY; QUALITY CONTROL; RADIONUCLIDE IMAGING; RECEPTORS, SOMATOSTATIN; RESEARCH DESIGN; SOMATOSTATIN;

EID: 77954960181     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1473-6     Document Type: Review

References (34)

1. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111) In-pentetreotide. J Nucl Med 2001;42(7):1134-8.
2. Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111) In-pentetreotide. Neuroendocrinology 2009;90(2):184-9.
3. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323(18):1246-9.
4. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 1998;25(6):639-58.
5. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam expe-rience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716-31.
6. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995;36(4):542-9.
7. Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendo-crine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995;25(3):251-61.
8. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008;26(6):963-70.
9. Wong KK, Cahill JM, Frey KA, Avram AM. Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendo-crine tumors. Acad Radiol 2010;17:291-7.
10. Steffen IG, Mehl S, Heuck F, Elgeti F, Furth C, Amthauer H, et al. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity? Clin Nucl Med 2009;34(12):869-73.
11. Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003;59(5):565-73.
12. Schillaci O, Scopinaro F, Angeletti S, Tavolaro R, Danieli R, Annibale B, et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 1996;37(9):1452-6.
13. Warner RR, O'dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin Nucl Med 2002;32(2):79-83.
14. Westlin JE, Janson ET, Arnberg H, Ahlström H, Oberg K, Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. Acta Oncol 1993;32(7-8): 783-6.
15. Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998;25(7):675-86.
16. Pichler R, Pichler J, Mustafa H, Nussbaumer K, Zaunmüller T, Topakian R. Somatostatin-receptor positive brain stem glioma visualized by octreoscan. Neuro Endocrinol Lett 2007;28(3):250-1.
17. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PP, Lamberts SW. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993;20(4):283-92.
18. Kälkner KM, Janson ET, Nilsson S, Carlsson S, Oberg K, Westlin JE. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res 1995;55(23 Suppl): 5801s-4.
19. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996;125(1):26-34.
20. Kwekkeboom DJ, Krenning EP, Kho GS, Breeman WA, Van Hagen PM. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 1998;25(9):1284-92.
21. Kwekkeboom DJ, Krenning EP. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Eur Radiol 1997;7(7):1103-9.
22. Briganti V, Sestini R, Orlando C, Bernini G, La Cava G, Tamburini A, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determina-tion of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 1997;3(12 Pt 1):2385-91.
23. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastro-enteropancreatic tract tumours. Q J Nucl Med 2000;44(1):42-9.
24. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25(10):1396-403.
25. Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999;40(4):539-53.
26. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancre-atic tumors. J Nucl Med 1997;38(6):853-8.
27. Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999;40(10):1602-8.
28. Khanna G, O'Dorisio MS, Menda Y, Glasier C, Deyoung B, Smith BJ, et al. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. Pediatr Blood Cancer 2008;50(3):561-6.
29. Kropp J, Hofmann M, Bihl H. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor? Anti-cancer Res 1997;17(3 B): 1583-8.
30. ICRP Publication 80. Radiation dose to patients from radio- pharmaceuticals. Ann ICRP 1998;28:3. Oxford: Pergamon.
31. ICRP Publication 62. Radiological protection in biomedical research. Ann ICRP 1991;22:3. Oxford: Pergamon.
32. ICRP Publication 53. Radiation dose to patients from radio- pharmaceuticals. Ann ICRP 1987;18:1-4. Oxford: Pergamon.
33. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP 2008;38(1-2): 1-197.
34. EANM Physics Committee, Busemann Sokole E, Plachcínska A, Britten A, EANM Working Group on Nuclear Medicine Instru-mentation Quality Control, Lyra Georgosopoulou M, et al. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging 2010;37:662-71.